The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer

Immune checkpoint blockade (ICB) therapy has evoked a prominent shift in anticancer therapy. Durable clinical antitumor activity to ICB has been observed in patients with ovarian cancer (OC). However, only a subset of patients derive clinical benefit, and immune-related adverse events (irAEs) caused...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yufei, Zuo, Fengli, Wang, Huiling, Jing, Jing, He, Xiujing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647049/
https://www.ncbi.nlm.nih.gov/pubmed/36389711
http://dx.doi.org/10.3389/fimmu.2022.1045957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647049/
https://www.ncbi.nlm.nih.gov/pubmed/36389711
http://dx.doi.org/10.3389/fimmu.2022.1045957

Ejemplares similares